Sanofi

SNY • Drug Manufacturers - General

$41.40

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL MUY FAVORABLEExcelenteConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$99.54B

Crecimiento

6.6%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 16.7%Crecimiento positivo de ingresos · 5.2%Flujo de caja libre positivo · 4.16Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 12.88

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 23 abr 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$41.40

Change0.00%

Shares Out2.41B

Market Cap$99.54B

52W Range40.89 - 52.68

Beta0.28

P/E14.98

P/S8.60

P/B1.33

P/FCF0.00

EV/Sales10.22

EV/EBITDA42.29

Price$41.40

Change0.00%

Shares Out2.41B

Market Cap$99.54B

52W Range40.89 - 52.68

Beta0.28

P/E14.98

P/S8.60

P/B1.33

P/FCF0.00

EV/Sales10.22

EV/EBITDA42.29

EV/FCF0.00

Earnings Yield6.67%

FCF Yield0.00%

Dividend Yield0.00%

Gross Margin72.07%

Oper. Margin20.54%

Profit Margin16.72%

Debt/Eq0.31

Current Ratio1.09

Quick Ratio0.29

Revenue 5Y6.57%

FCF 5Y10.88%

Target$49.00

Target Upside18.36%

Target Median$49.00

Target Range49.00 - 49.00

Volume10.18M

Avg Volume3.26M

EPS Surprise0.04

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

85/100

Fortaleza financiera

Deuda, caja, estabilidad

64/100

Potencial de crecimiento

Ingresos y expansión

71/100

Atractivo del precio

Barata o cara hoy

87/100

Por qué este puntaje▼

Márgenes estables o en mejora · 16.7%Crecimiento positivo de ingresos · 5.2%Flujo de caja libre positivo · 4.16Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 12.88Nivel de deuda manejable · 0.31

Analyst view

Analyst sentiment and price target

SNY

Analyst sentiment

Based on 27 analyst votes · 2026-10-20

70/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-31

Bajo

$49.00

Promedio

$49.50

Mediana

$49.50

Alto

$50.00

Resumen de la compañía

IPO: 7/1/2002

Industria: Drug Manufacturers - General

P/B i: 1.33

Deuda / Patrimonio i: 0.31

Margen operativo: 20.54%

Margen neto: 16.72%

ROE i: -

ROIC: -

Salud financiera

Puntaje13 / 20

Deuda / Patrimonio: 0.31

Ratio corriente: 1.09

Ratio rápido: 0.29

Estado: Good

Advertencias

Weak quick ratio

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Sanofi

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Fuente - Link

Competidores

AMGN BMY CELG-RI CVS GILD GSK HCA MDT PFE VRTX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics

CAMBRIDGE, England--(BUSINESS WIRE)--ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY) to develop and commercialize extended exposure ver.

Business Wire

Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System

Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple myeloma Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple myeloma

GlobeNewsWire

Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2 026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany.

GlobeNewsWire

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027 Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027

GlobeNewsWire

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-23	1.06	1.1	0.04
2026-01-29	0.84	0.89	0.05
2025-10-24	1.6	1.7	0.1
2025-07-31	0.96	0.9	-0.06
2025-04-24	0.9	0.94	0.04
2025-01-30	0.71	0.7	-0.01
2024-10-25	1.35	1.57	0.22
2024-07-25	0.86	0.93	0.07
2024-04-25	0.94	0.97	0.03
2024-02-01	0.94	0.89	-0.05
2023-10-27	1.37	1.39	0.02
2023-07-28	1.55	0.95	-0.6